Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
S1Bv7LdjhXPcSmXj
Listen
